Delving into the Latest Updates on Zhejiang Maitong Biopharmaceutical Co. Ltd. with Synapse

Overview

Tags

Neoplasms

Small molecule drug

Chemical drugs

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	4

Top 5 Drug Type	Count

Small molecule drug	3
Chemical drugs	1

Top 5 Target	Count

IDH1(Isocitrate dehydrogenase [NADP] cytoplasmic)	2
ME3(malic enzyme 3)	1
IDH2(Isocitrate dehydrogenase [NADP], mitochondrial)	1

[Translation] A multicenter, dose-escalation and cohort expansion, single-arm, open-label Phase I/IIa clinical study to evaluate the safety, tolerability, pharmacokinetic, pharmacodynamic characteristics and preliminary anti-tumor efficacy of MT-001 capsules in patients with locally advanced/metastatic solid tumors

I期主要目的：评价MT-001胶囊的安全性和耐受性，确定最大耐受剂量（MTD）和/或II期推荐剂量（RP2D）。次要目的：评价MT-001胶囊的药代动力学特征及代谢物谱；评价MT-001胶囊的药效动力学特征，以及药代动力学/药效动力学相关性；初步探索MT-001胶囊的抗肿瘤疗效。探索性终点：生物标志物探索性研究。 IIa期主要目的：评价MT-001胶囊在II期推荐剂量（RP2D）下的安全性和耐受性；评价MT-001胶囊在II期推荐剂量（RP2D）下的初步抗肿瘤疗效。次要目的：评价MT-001胶囊在II期推荐剂量（RP2D）下的抗肿瘤疗效；评价MT-001胶囊在II期推荐剂量（RP2D）下的药代动力学特征；药效动力学特征，以及药代动力学/药效动力学相关性。探索性终点：生物标志物探索性研究。

[Translation]

The main purpose of Phase I is to evaluate the safety and tolerability of MT-001 capsules and determine the maximum tolerated dose (MTD) and/or Phase II recommended dose (RP2D). Secondary objectives are to evaluate the pharmacokinetic characteristics and metabolite profile of MT-001 capsules; evaluate the pharmacodynamic characteristics of MT-001 capsules, as well as the pharmacokinetic/pharmacodynamic correlation; and preliminarily explore the anti-tumor efficacy of MT-001 capsules. Exploratory endpoints: biomarker exploratory studies. The main purpose of Phase IIa is to evaluate the safety and tolerability of MT-001 capsules at the Phase II recommended dose (RP2D); evaluate the preliminary anti-tumor efficacy of MT-001 capsules at the Phase II recommended dose (RP2D). Secondary objectives are to evaluate the anti-tumor efficacy of MT-001 capsules at the Phase II recommended dose (RP2D); evaluate the pharmacokinetic characteristics of MT-001 capsules at the Phase II recommended dose (RP2D); pharmacodynamic characteristics, and pharmacokinetic/pharmacodynamic correlation. Exploratory endpoints: biomarker exploratory studies.

Start Date26 Dec 2023

Sponsor / Collaborator

Zhejiang Maitong Biopharmaceutical Co. Ltd.

100 Clinical Results associated with Zhejiang Maitong Biopharmaceutical Co. Ltd.

Login to view more data

0 Patents (Medical) associated with Zhejiang Maitong Biopharmaceutical Co. Ltd.

Login to view more data

100 Deals associated with Zhejiang Maitong Biopharmaceutical Co. Ltd.

Login to view more data

100 Translational Medicine associated with Zhejiang Maitong Biopharmaceutical Co. Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 23 Dec 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

3

1

Phase 2 Clinical

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

MT-001(Zhejiang Meton) ( IDH1 )	IDH1 positive Solid Tumors More	Phase 2 Clinical
IDH2 inhibitors (Zhejiang Meton) ( IDH2 )	Neoplasms More	Preclinical
IDH1 inhibitors (Zhejiang Meton) ( IDH1 )	Neoplasms More	Preclinical
ME3 inhibitor (Maitong Biotechnology) ( ME3 )	Neoplasms More	Preclinical